{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "import os\n",
    "sys.path.append('..')\n",
    "\n",
    "from utils import ProcessDocument\n",
    "from langchain.vectorstores.faiss import FAISS\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "chunks = ProcessDocument(\"/Users/ansh/gpt_poc/protocols/protocol.pdf\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PF-07302048 (BNT162 RNA -Based COVID -19 Vaccines)  \n",
      "Protocol C4591001  \n",
      " \n",
      " \n",
      "Page 1  \n",
      " \n",
      " \n",
      "A PHASE 1/2 /3, PLACEBO -CONTROLLED, RANDOMIZED, OBSERVER -BLIND, \n",
      "DOSE -FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, \n",
      "IMMUNOGENICITY, AND EFFICACY OF SARS -COV -2 RNA VACCINE \n",
      "CANDIDATES AGAINST COVID -19 IN HEALTHY INDIVIDUALS  \n",
      " \n",
      "Study Sponsor:  BioNTech  \n",
      "Study Conducted By:  Pfizer  \n",
      "Study Intervention Number:  PF-07302048  \n",
      "Study Intervention Name:  RNA -Based COVID -19 Vaccine s \n",
      "US IND Number:  19736  \n",
      "EudraCT Number:  2020 -002641 -42 \n",
      "Protocol Number:  C4591001  \n",
      "Phase:  1/2/3 \n",
      "Short Title:  A Phase 1/2 /3 Study to Evaluate  the Safety, Tolerability, Immunogenicity, and \n",
      "Efficacy of RNA Vaccine Candidates Against C OVID -19 in Healthy Individuals\n"
     ]
    }
   ],
   "source": [
    "print(chunks.load_and_chunk()[0].page_content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "embedding_function = OpenAIEmbeddings(openai_api_key=\"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\")\n",
    "vector_store = FAISS.from_texts([c.page_content for c in chunks.load_and_chunk()], embedding_function)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(Document(page_content='PF-07302048 (BNT162 RNA -Based COVID -19 Vaccines)  \\nProtocol C4591001  \\n \\n \\nPage 94 opinion, the clinical picture is more indicative of a possible COVID -19 illness than vaccine \\nreactogenicity.  If, in the investigator’s opinion,  the symptoms are considered more likely to \\nbe vaccine reactogenicity, but a participant is required to demonstrate that they are  \\nSARS -CoV -2–negative, a local SARS -CoV -2 test may be performed: if positive, the \\nsymptoms should be recorded as a potential COVID -19 illness ; if not, the symptoms should \\nbe recorded  as AEs  (unless already captured in the reactogenicity e -diary) . \\nParticipants may utilize a COVID -19 illness e -diary through an application (se e Section 8.14) \\ninstalled on a provisioned device or on the participant’s own personal device to prompt \\nhim/her to r eport any symptoms.  Note that this does not substitute for a participant’s routine  \\nmedical care.   Therefore , participants  should be encouraged to seek care, if appropriate, from \\ntheir usual provider.  \\n• A diagnosis of COVID -19; \\n• Fever;  \\n• New or increased cough;  \\n• New or increased shortness of breath ;  \\n• Chills ;  \\n• New or increased muscle pain ;  \\n• New l oss of taste/smell ; \\n• Sore throat;  \\n• Diarrhea ; \\n• Vomiting .', metadata={}),\n",
       "  0.38413525),\n",
       " (Document(page_content='PF-07302048 (BNT162 RNA -Based COVID -19 Vaccines)  \\nProtocol C4591001  \\n \\n \\nPage 56 • Roche cobas SARS -CoV -2 real-time RT -PCR test (EUA200009/A001)  \\n• Abbott Molecular/RealTime SARS -CoV -2 assay (EUA200023/A001)  \\nTwo definitions of SARS -CoV -2–related cases , and SARS -CoV -2–related severe cases , will \\nbe considered  (for both , the onset date of the case will be the date that symptoms were first \\nexperienced by the participant ; if new symptoms are reported within 4 days after resolution \\nof all previo us symptoms, they will be considered as part of a single illness ): \\n• Confirmed COVID -19: presence of at least 1 of the following symptom s and \\nSARS -CoV -2 NAAT -positive during, or within 4 days before or after, the \\nsymptomatic period , either  at the central lab oratory  or at a local testing facility  (using \\nan acceptable  test):  \\n• Fever;  \\n• New or increased cough;  \\n• New or increased shortness of breath;  \\n• Chills;  \\n• New or increased muscle pain;  \\n• New loss of taste or smell;  \\n• Sore throat ; \\n• Diarrhea;  \\n• Vomiting . \\nThe second definition, which  may be updated as more is learn ed about COVID -19, will \\ninclude the following additional symptoms defined by  the CDC ( listed at \\nhttps://www.cdc.gov/coronavirus/2019 -ncov/symptoms -testing/symptoms.html) : \\n• Fatigue;  \\n• Headache;  \\n• Nasal congestion or runny nose;  \\n• Nausea . \\n• Confirmed severe COVID -19: confirmed COVID -19 and presence of at least 1 of the \\nfollowing:', metadata={}),\n",
       "  0.38596177),\n",
       " (Document(page_content='currently no vaccines or effective antiviral drugs to treat SARS -CoV -2 infections or the \\ndisease it causes, COVID -19.3 \\nA prophylactic, RNA -based SARS -CoV -2 vaccine provides one of the most flexible and \\nfastest approaches available to immunize against the emerging virus.4,5 \\nThe development of an RNA -based vaccine encoding a viral antigen, which is then expressed \\nby the vaccine recipient as a protein capable of eliciting protective immune responses, \\nprovides sig nificant advantages over more traditional vaccine approaches.  Unlike live \\nattenuated vaccines, RNA vaccines do not carry the risks associated with infection and may \\nbe given to people who cannot be administered live virus (eg, pregnant women and \\nimmunocom promised persons).  RNA -based vaccines are manufactured via a cell -free in \\nvitro transcription process, which allows an easy and rapid production and the prospect of \\nproducing high numbers of vaccination doses within a shorter time period than achieved wit h \\ntraditional vaccine approaches.  This capability is pivotal to enable the most effective \\nresponse in outbreak scenarios.', metadata={}),\n",
       "  0.3897117),\n",
       " (Document(page_content='observed for at least 30 minutes after vaccination.  \\nPotential for COVID -19 \\nenhancement.  Disease enhancement has been seen \\nfollowing vaccination  with respiratory \\nsyncytial virus  (RSV ), feline coronavirus , \\nand Dengue virus vaccines . Phase 1 excludes participant s with likely previous or current  COVID -19. In \\nPhase 2/ 3, temporary delay criteria defer vaccination of participants with \\nsymptoms of potential  COVID -19. All participants are followed for any \\npotential COVID -19 illness , including  markers of severity , and have blood \\nsamples taken for potential measurement of SA RS-CoV -2 antigen -specific \\nantibody and SARS -CoV -2 neutralizing titers .', metadata={}),\n",
       "  0.39450204)]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "vector_store.similarity_search_with_score(\"covid\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "import yaml\n",
    "def read_prompts_from_yaml(yaml_file):\n",
    "    print(yaml_file)\n",
    "    with open(yaml_file) as file:\n",
    "        prompts = yaml.safe_load(file)\n",
    "    return prompts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "../prediction/prompts.yml\n"
     ]
    }
   ],
   "source": [
    "import openai\n",
    "\n",
    "biopsy_prompt = read_prompts_from_yaml(\"../prediction/prompts.yml\")[\"assessment_level\"][\"biopsy\"]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'system': \"You are a clinical trial protocol analyst. Your task is to Answer the Question, based on  the Context. The context is made of chunks of texts from a single clinical protocol which comprises of multiple sections. Only Answer the Question when you can answer it based on the Context. Do not try to make up an answer. Don't make anything up. Select one or two quotes from the context that support your answer. Return in the following format { 'variable':'biopsy', 'value': 'Y' or 'N', 'metadata':{ Page number:  , Chunk number: , Section name: , Quote: } }\",\n",
       " 'user': \"Context: of study intervention  in Phase 1 , whichever is later .  These data will be monitored on an \\nongoing basis by the investigator (or medically qualified designee) and sponsor in order to \\npromptly identify and flag any event that potentially contributes to a stopping rule.  \\nThe sponsor study team will be unblinded du ring Phase  1, so will be able to assess whether \\nor not a stopping rule has been met on the basis of a participant ’s individual study \\nintervention allocation. The investigator (or an appropriate delegate at the investigator site) must  obtain a signed and \\ndated ICD before performing any study -specific procedures.  \\nThe full date of birth will be collected to critically evaluate the immune response and safety \\nprofile by age.  \\nStudy procedures and their timing are summarized in the SoA.  Protocol  waivers or  \\nexemptions are not allowed.  \\nSafety issues  should be discu ssed with the sponsor immediately upon occurrence or \\nawareness to determine whether  the participant should continue or discontinue study \\nintervention.  \\nAdherence to the study design requirements, including those specified in the SoA, is essential \\nand required for study conduct. PF-07302048 (BNT162 RNA -Based COVID -19 Vaccines)  \\nProtocol C4591001  \\n \\n \\nPage 52 • Measure the participant’s body temperature.  \\n• Perform urine pregnancy test on WOCBP as described in Section 8.2.6 . \\n• Discuss contraceptive use as described in Section 10.4. \\n• Ensure that the participant meets none of the temporary delay criteria as described in \\nSection 5.5. \\n• Unblinded site staff member(s) will dispense/administer 1 dose of study intervention \\ninto the deltoid muscle of the preferably nondominant arm.  Please refer to the IP \\nmanual for further instruction on this process.  \\n• Blinded site staff must observe the participant for at least 30 minutes after study \\nintervention administration for any acute reactions.  Record any acute reactions \\n(including time of onset) in the participant’s source documents and on the AE page of \\nthe CRF, and on an SAE form a s applicable.  \\n• The participant should continue to adhere to the normal visit schedule but must be \\nfollowed for nonserious AEs  for 1 month and SAEs for 6 months after the second \\ndose of BNT162b2.  This will require AEs to be elicited either by unscheduled \\ntelephone contact(s) and/or in -person visit(s).  \\n6.7. Intervention After the End of the Study  \\nNo intervention will be provided to study participants at the end of the study.  \\n7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT \\nDISCONTINUATION/WITHDRAWAL  \\n7.1. Discontin uation of Study Intervention  \\nIn rare instances, it may be necessary for a participant  to permanently discontinue study \\nintervention  (definitive discontinuation) .  Reasons for definitive discontinuation of study  \\nintervention may include the following : AEs; participant request; investigator request ; \\npregnancy; protocol deviation  (including no longer meeting all the inclusion criteria, or \\nmeeting 1 or more exclusion criteria) . In general, unless the investigator considers it unsafe \\nto administe r the second dose, or the participant does not wish to receive it, it is preferred PF-07302048 (BNT162 RNA -Based COVID -19 Vaccines)  \\nProtocol C4591001  \\n \\n \\nPage 40 Update as part of protocol amendment 3:  as data have become available from this study and \\nthe BNT162 -01 study in Germany, it was decided : \\n• To not study the BNT162a1 and BNT162c2 vaccine candidates at this time, so these \\ncandidates have been removed from the protocol;  and \\n• That lower dose levels of BNT162b1 and BNT162b2 warrant consideration.  \\nTherefore, a 2 0-µg dose level is formally included for both candidates . \\nUpdate as part of protocol amendment 4: the 5 0-µg dose level for BNT162b1 and BNT162b2 \\nis removed  and the 100-µg dose level for BNT162b2 is removed ; similar dose levels of \\nBNT162b3 may be studied as for BNT162b1 and BNT162b2.  \\nUpdate as part of protocol amendment 5: the vaccine candidate selected for Phase 2/3  \\nevaluation is BNT162b 2 at a dose of 30 µg.  BNT162b3 will not be studied.  \\n4.4. End of Study Definition  \\nA participant is considered to have completed the study if he/she has completed all phases of \\nthe study , including the last visit .  Note that participants enrolled in Phase  1 in groups that do \\nnot proceed to Phase 2/ 3 may be followed for fewer than 24 months (but no less than \\n6 months after the last vaccination).  \\nThe end of the study is defined as the date of last visit of the last participant  in the study.  \\n5. STUDY POPULATION  \\nThis study can fulfill its objectives only if appropriate participant s are enrolled.  The \\nfollowing eligibility criteria are designed to select participant s for whom participation in the \\nstudy is considered appropriate.  All r elevant medical and nonmedical conditions should be \\ntaken into consideration when deciding whether a particular participant  is suitable for this \\nprotocol .  \\nProspective approval of protocol deviations to recruitment and enrollment criteria , also \\nknown as protocol waivers or exemptions, is not permitted . \\n5.1. Inclusion Criteria\\n\\nQuestion: Is 'Biopsy' done during this study? [sigmoidscopy]\\n\\n\"}"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "biopsy_prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "def compose_prompt(context, query):\n",
    "    return \"Context: \" + context + \"\\n\\n\" + \"Question: \" + query + \"\\n\\n\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_context(query):\n",
    "    results = vector_store.similarity_search_with_score(query)\n",
    "    context = \" \".join([c[0].page_content for c in results])\n",
    "    return compose_prompt(context, query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "composed_prompt = get_context(biopsy_prompt[\"user\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "biopsy_prompt[\"user\"] = composed_prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "#write a function to convert this format \n",
    "#{\"system\": \"You are a helpful assistant.\",\n",
    "# \"user\": \"Who won the world series in 2020?\"}\n",
    "\n",
    "#into this format\n",
    "#messages=[\n",
    "#        {\"role\": \"system\", \"content\": \"You are a helpful assistant.\"},\n",
    "#        {\"role\": \"user\", \"content\": \"Who won the world series in 2020?\"},\n",
    "#        {\"role\": \"assistant\", \"content\": \"The Los Angeles Dodgers won the World Series in 2020.\"},\n",
    "#        {\"role\": \"user\", \"content\": \"Where was it played?\"}\n",
    "#    ]\n",
    "#)\n",
    "\n",
    "def convert_to_messages(prompt):\n",
    "    messages = []\n",
    "    for role in prompt:\n",
    "        messages.append({\"role\": role, \"content\": prompt[role]})\n",
    "    return messages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "response = openai.ChatCompletion.create(\n",
    "            model=\"gpt-3.5-turbo\",\n",
    "            messages=convert_to_messages(biopsy_prompt),\n",
    "            stream=False,\n",
    "            temperature=0.5,\n",
    "        )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{ 'variable':'biopsy', 'value': 'N', 'metadata':{ Page number:  52, Chunk number: 1, Section name: , Quote: \"No intervention will be provided to study participants at the end of the study.\" } }\n"
     ]
    }
   ],
   "source": [
    "print(response[\"choices\"][0][\"message\"][\"content\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
